CXCL10 Mutant with Enhanced GAG Binding for T-Cell Mobilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches targeting CXCL10 for inflammatory diseases are limited by their inability to effectively mobilize T-cells, as they neglect the crucial role of glycosaminoglycans in chemokine function and signaling.
Innovation Solution
A recombinant CXCL10 polypeptide with increased glycosaminoglycan (GAG) binding affinity is developed through specific amino acid substitutions, enhancing its ability to mobilize T-cells by improving its interaction with GAGs, thereby potentially treating inflammatory and immunological disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type CXCL10 is used, then the structure is simple and production is easy, but the GAG binding affinity is insufficient and T-cell mobilization is limited
Solution Approach 1:
The patent applies parameter changes by modifying specific amino acid residues in the CXCL10 protein sequence. Mutations at positions 12, 14, 20, and/or 25 alter the chemical properties of the protein, specifically increasing its affinity for glycosaminoglycans while maintaining the overall protein structure and function. This resolves the contradiction by changing molecular parameters to improve binding affinity without fundamentally redesigning the protein architecture.
Solution Approach 2:
The patent applies local quality by introducing specific mutations at defined positions (12, 14, 20, 25) within the CXCL10 sequence. These localized changes concentrate the functional improvement at specific binding regions while leaving the rest of the protein structure unchanged. This approach improves GAG binding affinity through targeted modifications rather than global structural changes.
2Productivity
If therapeutic approaches neglect GAG interaction, then the treatment design is simple, but T-cell mobilization capability is insufficient
Solution Approach 1:
The patent improves T-cell mobilization efficiency by changing the amino acid parameters of CXCL10 to enhance GAG binding. The mutations at specific positions modify the protein's interaction characteristics with glycosaminoglycans, which are essential for chemokine signaling and T-cell recruitment. This resolves the contradiction by optimizing molecular parameters to improve therapeutic efficacy.
Solution Approach 2:
The patent recognizes glycosaminoglycans as intermediary molecules that mediate between the chemokine CXCL10 and its receptor on T-cells. By enhancing CXCL10's binding to GAGs, the patent strengthens this intermediary interaction, which is crucial for establishing chemotactic gradients and facilitating T-cell migration. This approach incorporates the intermediary role of GAGs to improve therapeutic productivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified CXCL10 polypeptide demonstrates enhanced T-cell migration and chemotaxis, indicating its potential as a potent T-cell mobilizer in pathological conditions, such as solid tumors, with a significantly increased GAG binding affinity compared to wild-type CXCL10.
Implementation Method 1
CXCL10 binds to the receptor CXCR3... the interaction with cell-surface heparan sulfate proteoglycans is essential for their signalling... increased glycosaminoglycan (GAG) binding affinity... specifically the one or more substitution is Arginine (R) or Lysine (K)
Data Source
AI summary
Herein provided is a novel recombinant CXCL10 polypeptide with increased glycosaminoglycan (GAG) binding affinity compared to wild type CXCL10 and increasing T-cell mobilization and its use for preventing or treating inflammatory and immuno-logical disorders and auto-immune diseases.